LETTERS IN DRUG DESIGN & DISCOVERY, vol.15, no.1, pp.65-69, 2018 (SCI-Expanded)
Background: Platinum complexes as antitumor agents have received considerable attention due to the clinically approved and have been marketed worldwide such as cisplatin, carboplatin, oxaliplatin or marketed locally such as nedaplatin, lobaplatin and heptaplatin for treatment of various tumor diseases. However, those drugs still had their own defects and they exhibited side effects including nephrotoxicity, ototoxicity, neurotoxicity and bone marrow suppression. Therefore there is still continuing interest in the development of new platinum drugs avoiding their inherent resistance and toxicity.